$UTHR

84 stories mentioning UTHRUpdated 2d ago

Every FINWIRES story that references UTHR, newest first.

What are analysts saying about UTHR?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

BofA SecuritiesTarget revised65d ago
Price target$613from $620

What's the latest news on UTHR?

Wells Fargo Upgrades United Therapeutics to Overweight From Equalweight, Raises Price Target to $738 From $575

United Therapeutics (UTHR) has an average rating of buy and mean price target of $670.67, according to analysts polled by FactSet.

$UTHR

Insider Trading135d ago

United Therapeutics Insider Sold Shares Worth $5,726,062, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on April 30, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,726,062. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000014/xslF345X05/primarydocument.xml

$UTHR

Insider Trading135d ago

United Therapeutics Insider Sold Shares Worth $5,439,991, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on April 30, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,439,991. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000044/xslF345X05/primarydocument.xml

$UTHR

Insider Trading137d ago

United Therapeutics Insider Sold Shares Worth $5,396,353, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on April 28, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,396,353. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000042/xslF345X05/primarydocument.xml

$UTHR

Insider Trading138d ago

United Therapeutics Insider Sold Shares Worth $5,403,684, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & Chief Executive Officer, on April 27, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,403,684. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000041/xslF345X05/primarydocument.xml

$UTHR

Insider Trading138d ago

United Therapeutics Insider Sold Shares Worth $5,688,319, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on April 27, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,688,319. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000013/xslF345X05/primarydocument.xml

$UTHR

Insider Trading139d ago

United Therapeutics Insider Sold Shares Worth $5,365,678, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on April 24, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,365,678. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000040/xslF345X05/primarydocument.xml

$UTHR

Insider Trading142d ago

United Therapeutics Insider Sold Shares Worth $1,655,790, According to a Recent SEC Filing

Christopher Patusky, Director, on April 24, 2026, sold 2,910 shares in United Therapeutics (UTHR) for $1,655,790. Following the Form 4 filing with the SEC, Patusky has control over a total of 2,590 common shares of the company, with 1,490 shares held directly and 1,100 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000123142726000002/xslF345X05/primarydocument.xml

$UTHR

Insider Trading142d ago

United Therapeutics Insider Sold Shares Worth $5,437,340, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on April 23, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,437,340. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000039/xslF345X05/primarydocument.xml

$UTHR

Insider Trading142d ago

United Therapeutics Insider Sold Shares Worth $5,723,438, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on April 23, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,723,438. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000012/xslF345X05/primarydocument.xml

$UTHR

Insider Trading143d ago

United Therapeutics Insider Sold Shares Worth $5,477,366, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on April 22, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,477,366. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000038/xslF345X05/primarydocument.xml

$UTHR

Insider Trading145d ago

United Therapeutics Insider Sold Shares Worth $5,778,607, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on April 20, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,778,607. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000011/xslF345X05/primarydocument.xmlPrice: $566.26, Change: $-7.19, Percent Change: -1.25%

$UTHR

Insider Trading145d ago

United Therapeutics Insider Sold Shares Worth $5,489,424, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on April 20, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,489,424. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000036/xslF345X05/primarydocument.xmlPrice: $565.14, Change: $-8.30, Percent Change: -1.45%

$UTHR

Insider Trading146d ago

United Therapeutics Insider Sold Shares Worth $5,573,223, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on April 17, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,573,223. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000035/xslF345X05/primarydocument.xml

$UTHR

Insider Trading149d ago

United Therapeutics Insider Sold Shares Worth $5,771,765, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on April 16, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,771,765. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000010/xslF345X05/primarydocument.xml

$UTHR

Insider Trading149d ago

United Therapeutics Insider Sold Shares Worth $5,483,484, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on April 16, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,483,484. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000034/xslF345X05/primarydocument.xml

$UTHR

Insider Trading149d ago

United Therapeutics Insider Sold Shares Worth $578,880, According to a Recent SEC Filing

Christopher Patusky, Director, on April 17, 2026, sold 1,000 shares in United Therapeutics (UTHR) for $578,880. Following the Form 4 filing with the SEC, Patusky has control over a total of 2,590 common shares of the company, with 1,490 shares held directly and 1,100 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000123142726000001/xslF345X05/primarydocument.xml

$UTHR

Insider Trading150d ago

United Therapeutics Insider Sold Shares Worth $11,057,621, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on March 13, 2026, sold 19,075 shares in United Therapeutics (UTHR) for $11,057,621. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,797 common shares of the company, with 40,513 shares held directly and 639,284 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000033/xslF345X05/primarydocument.xml

$UTHR

Insider Trading152d ago

United Therapeutics Insider Sold Shares Worth $5,748,802, According to a Recent SEC Filing

James Edgemond, CFO and Treasurer, on April 13, 2026, sold 10,000 shares in United Therapeutics (UTHR) for $5,748,802. Following the Form 4 filing with the SEC, Edgemond has control over a total of 18,876 common shares of the company, with 18,876 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000163617826000009/xslF345X05/primarydocument.xml

$UTHR

Insider Trading153d ago

United Therapeutics Insider Sold Shares Worth $5,408,194, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on April 10, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,408,194. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 679,872 common shares of the company, with 40,513 shares held directly and 639,359 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000031/xslF345X05/primarydocument.xml

$UTHR

Showing 61-80 of 84

Track with the FINWIRES app suite

FolioX

Track UTHR in your portfolio

WheelAI

Analyze UTHR options with the wheel strategy

StockInsider

See market sentiment on UTHR